These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33731859)

  • 1. Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
    Lepage CC; Palmer MCL; Farrell AC; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
    Br J Cancer; 2021 May; 124(10):1699-1710. PubMed ID: 33731859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
    Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
    Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.
    Karst AM; Jones PM; Vena N; Ligon AH; Liu JF; Hirsch MS; Etemadmoghadam D; Bowtell DD; Drapkin R
    Cancer Res; 2014 Feb; 74(4):1141-52. PubMed ID: 24366882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced
    Thompson LL; Baergen AK; Lichtensztejn Z; McManus KJ
    Cancers (Basel); 2020 Feb; 12(3):. PubMed ID: 32106628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma.
    Kuhn E; Wang TL; Doberstein K; Bahadirli-Talbott A; Ayhan A; Sehdev AS; Drapkin R; Kurman RJ; Shih IeM
    Mod Pathol; 2016 Oct; 29(10):1254-61. PubMed ID: 27443516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; ; Bowtell D; Waring P
    Gynecol Oncol; 2018 Nov; 151(2):327-336. PubMed ID: 30209015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
    Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
    Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
    Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; ; ; Waring P; Caldon CE
    J Pathol Clin Res; 2022 Jul; 8(4):355-370. PubMed ID: 35384378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development.
    Sheu JJ; Choi JH; Guan B; Tsai FJ; Hua CH; Lai MT; Wang TL; Shih IeM
    J Pathol; 2013 Mar; 229(4):559-68. PubMed ID: 23378270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
    Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
    Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
    Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice.
    Aziz K; Limzerwala JF; Sturmlechner I; Hurley E; Zhang C; Jeganathan KB; Nelson G; Bronk S; Fierro Velasco RO; van Deursen EJ; O'Brien DR; Kocher JA; Youssef SA; van Ree JH; de Bruin A; van den Bos H; Spierings DCJ; Foijer F; van de Sluis B; Roberts LR; Gores GJ; Li H; van Deursen JM
    Gastroenterology; 2019 Jul; 157(1):210-226.e12. PubMed ID: 30878468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARK2 suppresses the proliferation of high-grade serous ovarian carcinoma via inducing the proteasomal degradation of ZNF703.
    Wang F; Li Y; Han Y; Zhang Y; Wang H; Wang L; Wang C; Guo M; Li P
    Med Oncol; 2024 Jul; 41(8):207. PubMed ID: 39043895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
    Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
    Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduced
    Neudorf NM; Thompson LL; Lichtensztejn Z; Razi T; McManus KJ
    Cells; 2022 Nov; 11(23):. PubMed ID: 36496990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.
    Zuo T; Liu R; Zhang H; Chang X; Liu Y; Wang L; Zheng P; Liu Y
    J Clin Invest; 2007 Dec; 117(12):3765-73. PubMed ID: 18008005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis and heterogeneity of ovarian cancer.
    Kroeger PT; Drapkin R
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):26-34. PubMed ID: 27898521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation.
    Piva R; Liu J; Chiarle R; Podda A; Pagano M; Inghirami G
    Mol Cell Biol; 2002 Dec; 22(23):8375-87. PubMed ID: 12417738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer.
    Nakamura K; Reid BM; Chen A; Chen Z; Goode EL; Permuth JB; Teer JK; Tyrer J; Yu X; Kanetsky PA; Pharoah PD; Gayther SA; Sellers TA; Lawrenson K; Karreth FA
    Am J Hum Genet; 2022 Jan; 109(1):116-135. PubMed ID: 34965383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of neddylation and deneddylation of cullin1 in SCFSkp2 ubiquitin ligase by F-box protein and substrate.
    Bornstein G; Ganoth D; Hershko A
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11515-20. PubMed ID: 16861300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.